

AREV LIFE SCIENCES GLOBAL CORP.
PRESS RELEASE

AREV CORPORATE UPDATE

VANCOUVER, BC / August 10, 2022 / AREV LIFE SCIENCES GLOBAL CORP. (CSE: AREV) (OTC: AREVF) (“AREV” or the “Company”) AREV Life Sciences Global Corporation announces a corporate update on progress of its business streams.

Arev, like many other companies, has felt the impact of the lock downs and changes in market conditions as a result of Covid-19, the war in Ukraine and now global inflation. We believe AREV is very well positioned to make a positive impact in the Clinical Nutrition Sector and in the area of Therapeutic Interventions.

AREV produces ingredients and formulates proprietary therapeutic interventions with plans to deliver innovation in clinical nutrition, proprietary supplements, topicals and rational drug design, based on science. The Company’s business model leverages its core competency of extraction to produce unique ingredients and compounds for its pipeline of products. The Company continues in the product development and pre-commercialization stage with an expectation that it will begin commercial sales in 2023.

“We noticed our messaging was not being understood so in an effort to clarify the activities of the company we have created business streams that give us flexibility for the future.”, stated Mike Withrow CEO of AREV. He went on to say, “ We get a lot done without massive dilution. This move gives us the focus needed for each business stream of the company and makes it easier for the market to understand the synergy between each unit.”

The Company has focused its operations as a fully integrated enterprise and is now organized to address three core market segments; 1) Specialty Ingredients with extraction of compounds for consumption and topical use; 2) Clinical Nutrition with next generation Ready to Use Therapeutic Foods (RUTFs) and 3)Technology through development of a commercial platform called Medicine Merchant™ which supports the growth and efficiency of the Cannabis marketplace.

1) Specialty Ingredients - Leveraging its core competency in extractions, bulk compounds are fractionated into therapeutic compounds. Arev’s strategy is focused on novel approaches to therapeutic interventions via nutrition, supplementation, and topical applications. The Company is conducting research into compounds that have been acknowledged to have unique therapeutic benefits. How such compounds work and in what dosage are questions the Company seeks to answer through its innovative research.

2) Clinical Nutrition - The company invests in research related to phytomedicinal and biologic discoveries of small molecule antivirals, anti-inflammatories and cellular regeneration. We now have a significant footprint in human nutrition including the development of a Ready-to-Use Therapeutic Food (RUTF) for Severe Acute Malnutrition (SAM) and an Enteral Formula targeting the long-term effects of COVID-19. AREV has identified a significant opportunity to fill the unmet global need for next generation products.

3) Medicine Merchant™ - The Company has invested in the development of a technology platform called Medicine Merchant. Developed from a database from a well-known high traffic cannabis seed site, the platform is designed as the next generation technology in support of the global cannabis industry. The enterprise system has been extended to be scalable and can be skinned to serve a multitude of commercial products and telemedicine. Dispensaries and Pharmacies can embed their branded store on Medicine Merchant. The benefit to the dispensary is a cost savings from not having to build, maintain and market a website. Users will receive exposure to their physical store via the high traffic to their virtual store embedded in Medicine Merchant. Traffic is generated by the Arev UX and Marketing Team.

Select dispensaries, processors and brand manufacturers can serve as distributors to fulfil the customer orders. Raw material suppliers can be matched to manufacturers and marketers of branded consumer goods.

For further information, contact Mike Withrow, arevlifesciences@gmail.com 778-929-6536. For more information visit www.arevlifesciences.com.

On behalf of the Board,

Mike Withrow
CEO & Director

About AREV Life Sciences Global Corp.

The Company is a fully integrated enterprise with competencies in: 1) extraction of compounds for consumption and topical use. 2) Clinical Nutrition and 3) A technology platform called Medicine Merchant. The Company produces ingredients and formulates exclusive therapeutic interventions with plans to deliver innovation in clinical nutrition, proprietary supplements, topicals and rational drug design, based on science. The Company's business model leverages its core competency of extraction to produce ingredients and compounds for its pipeline of products. The Company continues in the product development and pre-commercialization stage.

AREV is dedicated to designing and delivering innovation in rational drug design, driven by presenting global epidemiological characteristics of multiple challenges to international human and animal health. AREV is a member of both BIOTECANADA and The Biotechnology Innovation Organization (BIO).

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

FORWARD LOOKING INFORMATION

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in policies of the CSE) accepts responsibility for the adequacy or accuracy of this release. This news release may include forward-looking statements that are subject to risks and uncertainties. All statements within, other than statements of historical fact, are to be considered forward looking. Although the Company believes the expectations expressed in such forward looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include market prices, exploitation and exploration successes, and continued availability of capital and financing, and general economic, market or business conditions. There can be no assurances that such statements will prove accurate and, therefore, readers are advised to rely on their own evaluation of such uncertainties. We do not assume any obligation to update any forward-looking statements except as required under the applicable laws. This press release contains forward-looking statements. The use of any of the words "anticipate", "continue", "estimate", "expect", "may", "will", "project", "should", "believe" and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this press release. Actual results could differ materially from those currently anticipated due to a number of factors and risks various risk factors discussed in the Company's Management's Discussion and Analysis under the Company's profile on www.sedar.com.